Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J&J Ordered to Pay $72M Over Cancer Death Linked to Talcum Powder

By Drug Discovery Trends Editor | February 24, 2016

Credit: Wikimedia CommonsJohnson & Johnson was ordered by a St. Louis jury to pay $72 million to the family of a woman who died of ovarian cancer and said that her decades-use of the pharma company’s talc-based powder products contributed to the disease.

Jurors in the state’s court awarded the family of Jacqueline Fox $10 million in compensatory damages and $62 million of punitive damages, according to the family’s lawyers and court records. The verdict is the first financial award in a lawsuit over such claims.

J&J faces claims that it failed for decades to warn consumers that its talc-based products could cause cancer. The company is facing about 1,200 lawsuits claiming studies have linked its Baby Powder and Shower to Shower products to ovarian cancer. About a thousand of those have been filed in Missouri state court, and the remainder in New Jersey.

“We have no higher responsibility than the health and safety of consumers and we are disappointed with the outcome of the trial,” Carol Goodrich, a J&J spokesperson, told Bloomberg. “We sympathize with the plaintiff’s family but firmly believe the safety of cosmetic talc is supported by decades of scientific evidence.”

Fox, who lived in Birmingham, Alabama, claimed she used Baby Powder and Shower to Shower for feminine hygiene for more than 35 years. She was diagnosed with ovarian cancer three years ago, and died in October at age 62.

The trial lasted for three weeks, and deliberations were four hours long. Valeant Pharmaceuticals, which acquired the Shower to Shower brand in 2012, was not involved in the case.

Jere Beasley, a lawyer for Fox’s family said J&J “knew as far back as the 1980s of the risk,” and still continued “lying to the public, lying to the regulatory agencies,” according to a Reuters article.

J&J introduced a baby powder that uses cornstarch in the 1970s, but continues selling products that contain talc. The company maintains that talc is safe: “The evidence is very clear” that the cancer’s cause is not known, said Gene Williams, a lawyer for J&J.

Several studies have for decades linked talc powder with cancer, calling it a “possible carcinogen.” In 1971, British researchers analyzed 13 ovarian tumors under a microscope and found talc particles embedded in 10 of the tumors.

In 1982, the journal Cancer published the first study linking talc powder with ovarian cancer. Lead author Dr. Daniel Cramer, a gynecologist and Harvard Medical School professor, has since been involved in other studies on this association, his latest published in Epidemiology in December 2015. He testified in the J&J court case as a paid expert witness.

There have been approximately 20 epidemiological studies that have found increased rates of ovarian cancer risk for women using talc for hygienic reasons, although some studies have not found an association.

The evidence linking talc powder and ovarian cancer — many of the studies are case-control studies, rather than cohort studies — is weak, showing only a “modest increase,” according to the Cancer Research UK.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE